Name | 4-(Methylsulfonyl)-1-{3-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]phenyl}piperidine |
---|---|
Synonyms |
4-(Methylsulfonyl)-1-{3-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]phenyl}piperidine
Piperidine, 4-(methylsulfonyl)-1-[3-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-1,2,4-triazol-1-yl]methyl]phenyl]- IACS-10759 |
Description | IACS-10759 is a potent inhibitor of complex I of oxidative phosphorylation (OXPHOS). |
---|---|
Related Catalog | |
Target |
OXPHOS[1] |
In Vitro | IACS-10759 inhibits the conversion of NADH to NAD+ in an immunoprecipitated complex I assay at low nM concentrations[1]. |
In Vivo | IACS-10759 is orally bioavailable with excellent physicochemical properties in preclinical species and achieves significant in vivo efficacy with daily oral dosing of 10-25 mg/kg. There is a >50 day extension of median survival in an orthotopic AML cell line xenograft and robust regression in DLBCL and GBM xenograft models[1]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 768.0±70.0 °C at 760 mmHg |
Molecular Formula | C25H25F3N6O4S |
Molecular Weight | 562.564 |
Flash Point | 418.3±35.7 °C |
Exact Mass | 562.161011 |
LogP | 3.91 |
Vapour Pressure | 0.0±2.6 mmHg at 25°C |
Index of Refraction | 1.648 |
Storage condition | -20℃ |